摘要
肝癌是临床常见的恶性肿瘤之一,在全球最常见恶性肿瘤中居第六位,在肿瘤相关致死率中占第三位。由于多数肝癌患者确诊时已是晚期,且对于晚期原发性肝癌缺乏有效的治疗措施,肝癌的治疗仍然是临床一大难题。临床上放射性治疗和肝移植手术等只对早期肝癌有效,对于晚期原发性肝癌的治疗多采用全身系统性治疗,主要包括分子靶向药物治疗、化疗等,其中索拉非尼是晚期肝癌药物治疗的金标准。本文对晚期原发性肝癌药物治疗最新进展作一综述。
Hepatocellular carcinoma(HCC)is the sixth common primar^^tumor.and the third cause of cancer-related death worldwide.Despite the spread of HCC,its treatment is still a hard challenge,due to high rate of late diagnosis and to lack of therapeutic options for advanced disease.In fact radical surger and liver transplantation,the most radical therapeutic-approaches,are indicated only in case of early diagnosis.Systemic therapy is particularly important for patients with advanced HCC,including targeted agent therapy and chemotherapy,with sorafenib as the only standard treatment available.In this review,we discussed the current situation and progress of systemic therapies for the advanced HCC.
作者
崔婷婷
杨勇
CUI Tingting;YANG Yong(Institute of Pharmaceutical Science,China Pharmaceutical University,Nanjing 211198,China)
出处
《药学研究》
CAS
2018年第2期108-111,共4页
Journal of Pharmaceutical Research
关键词
晚期原发性肝癌
分子靶向治疗化疗
药物治疗
Hepatocellular carcinoma
Targeted agent therapy chemotherapy
Pharmacotherapy
